@article{Tunio_AlAsiri_Bayoumi_2016, title={EFFICACY AND SAFETY OF MULTI-TARGETED KINASE INHIBITORS IN PROGRESSIVE, RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCERS: A META-ANALYSIS}, volume={2}, url={https://journals.sfu.ca/jcas/index.php/jcas/article/view/50}, DOI={10.37029/jcas.v2i1.50}, abstractNote={<div class="page" title="Page 1"><div class="layoutArea"><div class="column"><p><span>Purpose: </span><span>A meta-analysis was conducted to evaluate the impact of oral multitargeted kinase inhibitors (MTKIs) in radioactive-iodine refractory locally advanced, recurrent/metastatic differentiated thyroid cancer (DTC) on disease control rate (DCR), progression-free survival (PFS) and overall survival (OS) rates. </span></p><p><span>Materials and Methods: </span><span>The PubMed/MEDLINE, CANCERLIT, EMBASE, Cochrane Library database and other search engines were searched to identify randomised controlled trials (RCTs) comparing MTKIs with placebo in </span><span>locally advanced, recurrent/metastatic DTC. Pooled data were expressed as odds ratio (OR), with 95% con dence intervals (CIs, Mantel–Haenszel xed-effect model). </span></p><p><span>Results: </span><span>Three RCTs with a total patient population of 954 patients were identi ed. The use of MTKIs was associated </span><span>with improved PFS (OR: 0.262, 95% CI: 0.19–0.35; heterogeneity (I2) = 22.4%; </span><span>P </span><span>&lt; 0.0001), improved DCR (complete and partial responses + stable disease, </span><span>P </span><span>&lt; 0.0001) and improved OS 0.66, 95% CI: 0.46–0.96 (I2 = 43%, </span><span>P </span><span>= 0.034). </span><span>Lenvatinib (compliance = 87%) was associated with more grade ≥3 hypertension. However, its other adverse effects </span><span>were much lower than sorafenib (compliance = 56%) and vandetanib. </span></p><p><span>Conclusion: </span><span>In radioactive iodine-refractory recurrent, metastatic DTC patients, lenvatinib and sorafenib were associated with improved PFS, DRC and OS rates, while the compliance was better with lenvatinib. </span></p><p><span>Key words: </span><span>Meta-analysis, multitargeted kinase inhibitors, progressive differentiated thyroid cancer, radioactive iodine- refractory </span></p></div></div></div&gt;}, number={1}, journal={Journal of Cancer & Allied Specialties}, author={Tunio, Mutahir A and AlAsiri, Mushabbab and Bayoumi, Yasser}, year={2016}, month={May} }